Maximum percent improvement from baseline in sum of the product of greatest diameters (SPD) based on mean DI between first dose and first disease assessment. Ninety-five percent of patients with high DI (above the mean) experienced a >50% reduction in SPD vs 82% of patients with low DI (below the mean).